New combo for tough leukemia shows promise, but trial cut short
NCT ID NCT05268003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of three drugs—ponatinib, venetoclax, and mini-hyper CVD chemotherapy—in people with relapsed or refractory T-cell acute lymphoblastic leukemia. The goal was to see if the combo could improve remission rates. However, the study was terminated early after enrolling only 4 participants, so we have very little data on how well it works or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ponatinib, venetoclax, and mini-hyper CVD chemotherapy
What this could lead to
If it works, this could offer a new treatment option for patients with hard-to-treat T-cell acute lymphoblastic leukemia.
What could go wrong
The trial was terminated early with only 4 participants, so results are very limited. It is unclear if the combination is safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States